Provided by Tiger Fintech (Singapore) Pte. Ltd.

Argenx SE

555.11
-34.9500-5.92%
Post-market: 555.110.00000.00%19:55 EDT
Volume:547.39K
Turnover:308.81M
Market Cap:33.86B
PE:43.44
High:582.72
Open:575.41
Low:553.20
Close:590.06
Loading ...

Company Profile

Company Name:
Argenx SE
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
1599
Office Location:
Laarderhoogtweg 25,Amsterdam,Noord-Holland,Netherlands
Zip Code:
1101 EB
Fax:
- -
Introduction:
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Directors

Name
Position
Tim Van Hauwermeiren
Chief Executive Officer and Executive Director
A. A. Rosenberg
Non-Executive Director
David L. Lacey
Non-Executive Director
J. Donald deBethizy
Non-Executive Director
James M. Daly
Non-Executive Director
Pamela Klein
Non-Executive Director
Peter K. M. Verhaeghe
Non-Executive Director and chairperson
Werner Lanthaler
Non-Executive Director and vice chairperson

Shareholders

Name
Position
Tim Van Hauwermeiren
Chief Executive Officer and Executive Director
Keith Woods
Chief Operating Officer
Eric Castaldi
Chief Financial Officer
Arjen Lemmen
VP Corporate Development & Strategy
Dirk Beeusaert
General Counsel
Hans de Haard
Chief Scientific Officer
Wim Parys
Chief Medical Officer